Published: 24 June 2024
Consultations
Clozapine Survey/Consultation 2023
Summary
- Medsafe carried out an online voluntary survey/consultation to gather information about people’s experiences with clozapine in New Zealand.
- People who take clozapine, whānau, family and/or caregivers of people who take clozapine, and healthcare professionals supporting people who take clozapine could participate.
- We received 187 valid responses via the consultation tool.
- Download the Clozapine Consultation 2023 (PDF, 728 KB, 46 pages) report to view a summary of the information provided by participants.
About the consultation
Many people experience significant benefits from taking clozapine. However, clozapine can also cause some significant side effects. There are a number of monitoring requirements for clozapine to manage the risk of these side effects. People who take clozapine and the healthcare professionals who support them may experience challenges with clozapine side effects and the monitoring requirements.
From 7 August 2023 to 6 October 2023, Medsafe carried out an online voluntary survey/consultation to gather information about people’s experiences with clozapine in New Zealand. This was an information gathering exercise to understand local real-life experiences with clozapine use to inform the Medicines Adverse Reaction Committee’s* as part of a review of clozapine safety and monitoring requirements.
Further information about why we consulted on clozapine is outlined in the Clozapine Consultation 2023 report.
Responses received
We received 187 valid responses via the consultation tool.
You can view the submissions that we have got permission to publish.
Medsafe would like to thank all those who participated.
Summary of responses
Medsafe has summarised the responses in the Clozapine Consultation 2023 report (PDF, 728 KB, 46 pages).
The information provided has been grouped into 3 sections:
- summary of participants
- consumer experiences
- healthcare professional experiences
Each survey question is presented. Where applicable for open-ended questions, responses have been summarised and grouped into themes.
Next steps
The Clozapine Consultation 2023 report will be presented to the Medicines Adverse Reaction Committee alongside other information as part of a review of clozapine safety and monitoring requirements.
Enquiries
For any questions about this consultation, please email: medsafeadrquery@health.govt.nz
*The Medicines Adverse Reaction Committee (MARC) is an expert committee which discusses the safety of medicines.
